Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Plasma cell differentiation and multiple myeloma.Curr Opin Immunol. 2004; 16: 226-234
- Regulation of plasma-cell development.Nat Rev Immunol. 2005; 5: 230-242
- The generation of antibody-secreting plasma cells.Nat Rev Immunol. 2015; 15: 160-171
- Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival.J Exp Med. 2000; 192: 813-821
- The long-term survival of plasma cells.Scand J Immunol. 2011; 73: 508-511
- BAFF AND APRIL: a tutorial on B cell survival.Annu Rev Immunol. 2003; 21: 231-264
- BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.Blood. 2004; 103: 3148-3157
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.Blood. 2008; 111: 2755-2764
- The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity.J Immunol. 2002; 169: 4213-4221
- The generation of antibody-secreting plasma cells.Nat Rev Immunol. 2015; 15: 160-171
- Multiple myeloma: evolving genetic events and host interactions.Nat Rev Cancer. 2002; 2: 175-187
- Pathogenesis of myeloma.Annu Rev Pathol. 2011; 6: 249-274
- Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.Blood. 1992; 80: 2326
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.Leukemia. 2009; 23: 3-9
- Multiple myeloma: current perspectives.Clin Lab Med. 2011; 31 (x): 699-724
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.Br J Haematol. 2003; 121: 749-757
- Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma.Blood. 1972; 40: 719-724
- Monoclonal gammopathies in the adult population of Finistère, France.J Clin Pathol. 1982; 35: 63-68
- Frequency of pathological proteins (M-components) on 6,995 sera from an adult population.Acta Med Scand. 1966; 179: 235-247
- Pathogenesis beyond the cancer clone(s) in multiple myeloma.Blood. 2015; 125: 3049-3058
- The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.Am J Pathol. 1997; 151: 343-351
- Smoldering multiple myeloma.Blood. 2015; 125: 3069
- New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.Blood. 2007; 110: 2586-2592
- Minimal residual disease studies by flow cytometry in acute leukemia.Acta Haematol. 2004; 112: 8-15
- Cancer statistics, 2016.CA Cancer J Clin. 2016; 66: 7-30
- Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.Haematologica. 2014; 99: 163-171
- Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique.Blood. 2001; 97: 822-825
- Primary plasma cell leukaemia.Br J Haematol. 1994; 88: 754-759
- Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.Blood. 1999; 93: 1032-1037
- Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvement.Br J Haematol. 2010; 151: 525-527
- Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.Chin Med J. 2014; 127: 2765-2770
- The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.Blood. 2011; 117: 3613-3616
- Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.Am J Pathol. 1998; 152: 1655-1665
- Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.Haematologica. 2005; 90: 1365-1372
- Immunophenotyping of acute leukemias and myelodysplastic syndromes.Cytometry A. 2004; 58: 62-71
- Minimal residual disease monitoring by flow cytometry.Best Pract Res Clin Haematol. 2003; 16: 599-612
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.Leukemia. 2012; 26: 1908-1975
- Immunologic classification of leukemia and lymphoma.Blood. 1986; 68: 1-31
- Immunophenotyping of leukaemias and non-Hodgkin's lymphomas. Immunological markers and their CD codes.Neth J Med. 1988; 33: 298-314
- Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry.Blood. 1990; 76: 1739-1747
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol. 2016; 17: e328-e346
- Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.Br J Haematol. 1991; 77: 185-190
- Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.Blood. 2002; 100: 3095-3100
- Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.Blood. 2002; 99: 1853-1856
- Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.Cytometry B Clin Cytom. 2010; 78: 239-252
- Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration.Br J Haematol. 2006; 133: 530-532
- The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells.Haematologica. 2006; 91: 972-975
- Phenotypic difference of normal plasma cells from mature myeloma cells.Blood. 1993; 81: 2658-2663
- Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.J Clin Oncol. 2008; 26: 2737-2744
- Immunophenotyping of plasma cells in multiple myeloma.Methods Mol Med. 2005; 113: 5-24
- Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression.Blood Cells Mol Dis. 2004; 32: 293-301
- Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology.Cytometry B Clin Cytom. 2010; 78: 231-238
- Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma.Cytometry B Clin Cytom. 2016; 90: 61-72
- Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.Cytometry B Clin Cytom. 2016; 90: 91-100
- Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.Cytometry B Clin Cytom. 2016; 90: 40-46
- Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).Best Pract Res Clin Haematol. 2002; 15: 105-118
- Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part V—assay performance criteria.Cytometry B Clin Cytom. 2013; 84: 315-323
- 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia.Cytometry B Clin Cytom. 2007; 72: S14-S22
- Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part II—preanalytical issues.Cytometry B Clin Cytom. 2013; 84: 286-290
- Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part I—rationale and aims.Cytometry B Clin Cytom. 2013; 84: 282-285
- Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part IV—postanalytic considerations.Cytometry B Clin Cytom. 2013; 84: 309-314
- 2006 Bethesda International Consensus Conference on flow cytometric immunophenotyping of hematolymphoid neoplasia.Cytometry B Clin Cytom. 2007; 72: S3
- Validation and quality control in clinical flow cytometry.in: Kottke-Marchant K. Davis B.H. Laboratory Hematology Practice. Wiley-Blackwell, Oxford2012: 115-130
- Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part III—analytical issues.Cytometry B Clin Cytom. 2013; 84: 291-308
- Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.Cytometry B Clin Cytom. 2016; 90: 31-39
- Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.Cytometry B Clin Cytom. 2016; 90: 26-30
- Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds.Cytometry A. 2015; 87: 145-156
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Haematologica. 2008; 93: 431-438
- The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy.Haematologica. 2006; 91: 1234-1240
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Leukemia. 2017; ([Epub ahead of print])
- Single-tube 10-fluorochrome analysis for efficient flow cytometric evaluation of minimal residual disease in plasma cell myeloma.Am J Clin Pathol. 2016; 146: 41-49
- MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.Blood Adv. 2017; 1: 728
- Cell surface markers in multiple myeloma.Mayo Clin Proc. 1994; 69: 684-690
- CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.Br J Haematol. 2003; 121: 36-43
- Lack of CD27 in myeloma delineates different presentation and outcome.Br J Haematol. 2006; 132: 168-170
- CD28, a marker associated with tumoral expansion in multiple myeloma.Clin Cancer Res. 1998; 4: 1521-1526
- An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.Clin Exp Immunol. 1988; 72: 351-356
- Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression.Blood. 2001; 98: 187-193
- CD28 expressed on malignant plasma cells induces a pro-survival and immunosuppressive microenvironment.J Immunol. 2011; 187: 1243-1253
- Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.Proc Natl Acad Sci U S A. 1980; 77: 1588-1592
- The characterization and function of human immunoregulatory T lymphocyte subsets.Immunol Today. 1981; 2: 69-75
- A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy.Immunol Rev. 2003; 194: 105-111
- Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.J Clin Oncol. 2005; 23: 5668-5674
- Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.Haematologica. 2004; 89: 547-551
- Adhesion molecules on human myeloma cells—significant changes in expression related to malignancy, tumor spreading, and immortalization.Cancer Res. 1995; 55: 3647-3653
- The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.Leukemia. 1998; 12: 1977-1982
- Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.Am J Pathol. 2002; 160: 1293-1299
- Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.Leuk Lymphoma. 2004; 45: 61-65
- Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring.Cytometry B Clin Cytom. 2005; 63: 1-9
- Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.Leukemia. 2012; 26: 1862-1869
- CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.Leuk Res. 2008; 32: 379-382
- CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.Haematologica. 2011; 96: 328-332
- C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.Leuk Lymphoma. 2004; 45: 2281-2289
- Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.Blood. 1993; 81: 767-774
- Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface.J Biol Chem. 2003; 278: 12888-12893
- Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.Br J Haematol. 1997; 99: 368-371
- The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.Br J Haematol. 1998; 100: 637-646
- Interactions of syndecan-1 and heparin with human collagens.Glycobiology. 1994; 4: 327-332
- Optimizing a multi-colour immunophenotyping assay.Clin Lab Med. 2007; 27 (v): 469
- A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Leukemia. 2016; 30: 929-936
- Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.Blood. 2005; 106: 2276-2279
- Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.Blood. 2006; 107: 3384-3388
- Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.Am J Clin Pathol. 2004; 121: 482-488
- Reagents and cell staining for immunophenotyping by flow cytometry.in: McManus L.M. Mitchell R.N. Pathobiology of human disease. Elsevier, San Diego (CA)2014: 3678-3701
- Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients.Br J Haematol. 2000; 109: 438-446
- A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med. 2003; 348: 2609-2617
- Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.Clin Chem. 2001; 47: 673-680
- Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.Blood. 2010; 115: 3655-3663
- A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.N Engl J Med. 1996; 335: 91-97
- Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.Blood. 1997; 89: 789-793
- Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.Cancer. 2006; 106: 1958-1966
- Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.J Clin Oncol. 2008; 26: 5775-5782
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.Br J Haematol. 2008; 143: 46-53
- Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.Blood. 2009; 114: 1299-1305
- Multiple myeloma: recent progress in diagnosis and treatment.J Clin Exp Hematop. 2012; 52: 149-159
- Clinical translation in multiple myeloma: from bench to bedside.Semin Oncol. 2013; 40: 549-553
- Current strategies for treatment of relapsed/refractory multiple myeloma.Expert Rev Hematol. 2014; 7: 97-111
- The role of immunotherapy in multiple myeloma.Pharmaceuticals. 2016; 9: 3
- Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDA-NCI roundtable symposium.Am J Hematol. 2014; 89: 1159-1160
- Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.Blood. 2016; 127: 3165
- Minimal residual disease: what are the minimum requirements?.J Clin Oncol. 2014; 32: 475-476
- Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.J Clin Oncol. 2013; 31: 2540-2547
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.Bone Marrow Transplant. 2016; 51: 1565-1568
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.Blood. 2008; 112: 4017-4023
- Variables affecting the quantitation of CD22 in neoplastic B cells.Cytometry B Clin Cytom. 2011; 80: 83-90
- Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders.Leukemia. 2007; 21: 2043-2046
- Minimal residual disease assessment in the context of multiple myeloma treatment.Curr Hematol Malig Rep. 2016; 11: 118-126
- Technical issues: flow cytometry and rare event analysis.Int J Lab Hematol. 2013; 35: 344-350
- Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.Am J Clin Pathol. 2002; 117: 952-958
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.Leukemia. 2013; 27: 142-149
- Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach.Blood. 2009; 114: 33-37
- Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.Biol Blood Marrow Transplant. 2011; 17: 1133-1145
- Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.Blood. 2013; 121: 3413-3419
- New approaches to management of multiple myeloma.Curr Treat Options Oncol. 2014; 15: 157-170
- Cytogenetics and molecular cytogenetics in multiple myeloma.Eur J Cancer. 2006; 42: 1520-1529
- Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.Br J Haematol. 1998; 102: 1115-1123
- Autologous hematopoietic stem-cell transplantation for multiple myeloma.N Engl J Med. 2009; 360: 2645-2654
- Treatment of multiple myeloma.Nat Rev Clin Oncol. 2011; 8: 479-491
- New monoclonal antibodies on the horizon in multiple myeloma.Ther Adv Hematol. 2017; 8: 41-53
- Potential role of daratumumab in the treatment of multiple myeloma.Onco Targets Ther. 2014; 7: 1095-1100
- Robust isolation of malignant plasma cells in multiple myeloma.Blood. 2014; 123: 1336-1340
- CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.Crit Rev Oncol Hematol. 2013; 88: 168-177
- Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Leukemia. 2014; 28: 391-397
- Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.Exp Hematol. 2000; 28: 1039-1045
- Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.Leukemia. 2014; 28: 1299-1307
- Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial.Blood. 2015; 126: 191
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood. 2014; 123: 3073-3079
- Deep Igh sequencing identifies an ongoing somatic hypermutation process with complex and evolving clonal architecture in myeloma.Blood. 2015; 126: 21
- Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.Cytometry B Clin Cytom. 2016; 90: 73-80
- Myeloma minimal residual disease testing in the United States: evidence of improved standardization.Am J Hematol. 2016; 91: E502-E503
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.Leukemia. 2013; 27: 1659-1665
- High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.Sci Transl Med. 2012; 4: 134ra163
- Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.Leukemia. 2003; 17: 1013-1034
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.Blood. 2012; 119: 687-691
- Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.J Clin Oncol. 2011; 29: 1627-1633
- Assessment of minimal residual disease in myeloma and the need for a consensus approach.Cytometry B Clin Cytom. 2016; 90: 21-25
- New criteria for response assessment: role of minimal residual disease in multiple myeloma.Blood. 2015; 125: 3059
Article info
Footnotes
Disclosure Statement: The authors have no commercial or financial conflicts of interest to disclose.
Flow cytometry services were provided by the Flow and Image Cytometry Core facility at the Roswell Park Cancer Institute, which is supported in part by the NCI Cancer Center Support Grant 5P30 CA016056.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
